<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <amendments />
    <committeeReports>
      <committeeReport>
        <citation>H. Rept. 115-201</citation>
      </committeeReport>
    </committeeReports>
    <billType>HR</billType>
    <constitutionalAuthorityStatementText><![CDATA[<pre>From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. WALDEN:H.R. 2430.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8, Clause 3 of the United StatesConstitution.[Page H4223]</pre>]]></constitutionalAuthorityStatementText>
    <recordedVotes />
    <cosponsors>
      <item>
        <sponsorshipWithdrawnDate />
        <bioguideId>P000034</bioguideId>
        <district>6</district>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <identifiers>
          <lisID>887</lisID>
          <gpoId>8048</gpoId>
          <bioguideId>P000034</bioguideId>
        </identifiers>
        <fullName>Rep. Pallone, Frank, Jr. [D-NJ-6]</fullName>
        <party>D</party>
        <firstName>FRANK</firstName>
        <sponsorshipDate>2017-05-16</sponsorshipDate>
        <lastName>PALLONE</lastName>
        <middleName />
        <state>NJ</state>
      </item>
      <item>
        <sponsorshipWithdrawnDate />
        <bioguideId>B001248</bioguideId>
        <district>26</district>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <identifiers>
          <bioguideId>B001248</bioguideId>
          <gpoId>8182</gpoId>
          <lisID>1751</lisID>
        </identifiers>
        <fullName>Rep. Burgess, Michael C. [R-TX-26]</fullName>
        <party>R</party>
        <firstName>Michael</firstName>
        <sponsorshipDate>2017-05-16</sponsorshipDate>
        <lastName>Burgess</lastName>
        <middleName>C.</middleName>
        <state>TX</state>
      </item>
      <item>
        <sponsorshipWithdrawnDate />
        <bioguideId>G000410</bioguideId>
        <district>29</district>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <identifiers>
          <bioguideId>G000410</bioguideId>
          <lisID>462</lisID>
          <gpoId>8185</gpoId>
        </identifiers>
        <fullName>Rep. Green, Gene [D-TX-29]</fullName>
        <party>D</party>
        <firstName>GENE</firstName>
        <sponsorshipDate>2017-05-16</sponsorshipDate>
        <lastName>GREEN</lastName>
        <middleName />
        <state>TX</state>
      </item>
    </cosponsors>
    <laws />
    <policyArea>
      <name>Health</name>
    </policyArea>
    <relatedBills>
      <item>
        <latestAction>
          <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 76.</text>
          <actionDate>2017-05-11</actionDate>
        </latestAction>
        <number>934</number>
        <latestTitle>FDA Reauthorization Act of 2017</latestTitle>
        <congress>115</congress>
        <type>S</type>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>House</identifiedBy>
          </item>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestAction>
          <text>Referred to the Subcommittee on Health.</text>
          <actionDate>2017-03-24</actionDate>
        </latestAction>
        <number>1652</number>
        <latestTitle>Over-the-Counter Hearing Aid Act of 2017</latestTitle>
        <congress>115</congress>
        <type>HR</type>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestAction>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
          <actionDate>2017-03-21</actionDate>
        </latestAction>
        <number>670</number>
        <latestTitle>Over-the-Counter Hearing Aid Act of 2017</latestTitle>
        <congress>115</congress>
        <type>S</type>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestAction>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
          <actionDate>2017-05-04</actionDate>
        </latestAction>
        <number>1048</number>
        <latestTitle>Enhanced Clinical Trial Design Act of 2017</latestTitle>
        <congress>115</congress>
        <type>S</type>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestAction>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
          <actionDate>2017-05-08</actionDate>
        </latestAction>
        <number>1069</number>
        <latestTitle>Medical Device Safety Monitoring Act</latestTitle>
        <congress>115</congress>
        <type>S</type>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <subjects>
      <billSubjects>
        <legislativeSubjects />
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <latestAction>
      <text>Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 174.</text>
      <actionDate>2017-07-17</actionDate>
      <links />
    </latestAction>
    <notes />
    <originChamber>House</originChamber>
    <actions>
      <actionTypeCounts>
        <billReferrals>1</billReferrals>
        <designationOfSpeakerProTempore>1</designationOfSpeakerProTempore>
        <introducedInHouse>1</introducedInHouse>
        <considerationByHouse>1</considerationByHouse>
        <passedAgreedToInHouse>1</passedAgreedToInHouse>
        <placedOnCalendarSection>2</placedOnCalendarSection>
        <placeholderTextForH>3</placeholderTextForH>
        <motionToReconsiderResults>1</motionToReconsiderResults>
        <committeeReportOfABill>1</committeeReportOfABill>
        <introducedInTheHouse>1</introducedInTheHouse>
        <reportedToHouse>1</reportedToHouse>
        <unionCalendarAssignment>1</unionCalendarAssignment>
        <motionMadeToSuspendTheRules>1</motionMadeToSuspendTheRules>
        <actionStageOverride>1</actionStageOverride>
        <generalDebate>1</generalDebate>
        <finalPassageUnderSuspensionOfTheRulesResults>1</finalPassageUnderSuspensionOfTheRulesResults>
      </actionTypeCounts>
      <actionByCounts>
        <senate>2</senate>
        <houseOfRepresentatives>17</houseOfRepresentatives>
      </actionByCounts>
      <item>
        <actionDate>2017-07-17</actionDate>
        <committee />
        <links />
        <sourceSystem>
          <name>Senate</name>
          <code>0</code>
        </sourceSystem>
        <text>Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 174.</text>
        <type>Calendars</type>
      </item>
      <item>
        <actionDate>2017-07-13</actionDate>
        <committee />
        <links />
        <sourceSystem>
          <name>Senate</name>
          <code>0</code>
        </sourceSystem>
        <text>Received in the Senate. Read the first time. Placed on Senate Legislative Calendar under Read the First Time.</text>
        <type>Calendars</type>
      </item>
      <item>
        <actionCode>H38310</actionCode>
        <text>Motion to reconsider laid on the table Agreed to without objection.</text>
        <links />
        <actionTime>14:21:54</actionTime>
        <committee />
        <actionDate>2017-07-12</actionDate>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <type>Floor</type>
      </item>
      <item>
        <actionCode>H37300</actionCode>
        <text>On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5454-5477)</text>
        <links>
          <link>
            <name>H5454-5477</name>
            <url>https://www.congress.gov/congressional-record/volume-163/house-section/page/H5454-5477</url>
          </link>
        </links>
        <actionTime>14:21:52</actionTime>
        <committee />
        <actionDate>2017-07-12</actionDate>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <type>Floor</type>
      </item>
      <item>
        <actionCode>8000</actionCode>
        <text>Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.</text>
        <links />
        <actionTime>14:21:52</actionTime>
        <committee />
        <actionDate>2017-07-12</actionDate>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <type>Floor</type>
      </item>
      <item>
        <actionCode>H8D000</actionCode>
        <text>DEBATE - The House proceeded with forty minutes of debate on H.R. 2430.</text>
        <links>
          <link>
            <name>H.R. 2430</name>
            <url>https://www.congress.gov/bill/115th-congress/house-bill/2430</url>
          </link>
        </links>
        <actionTime>13:33:38</actionTime>
        <committee />
        <actionDate>2017-07-12</actionDate>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <type>Floor</type>
      </item>
      <item>
        <actionCode>H30000</actionCode>
        <text>Considered under suspension of the rules. (consideration: CR H5454-5483)</text>
        <links>
          <link>
            <name>H5454-5483</name>
            <url>https://www.congress.gov/congressional-record/volume-163/house-section/page/H5454-5483</url>
          </link>
        </links>
        <actionTime>13:33:37</actionTime>
        <committee />
        <actionDate>2017-07-12</actionDate>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <type>Floor</type>
      </item>
      <item>
        <actionCode>H30300</actionCode>
        <text>Mr. Walden moved to suspend the rules and pass the bill, as amended.</text>
        <links />
        <actionTime>13:33:23</actionTime>
        <committee />
        <actionDate>2017-07-12</actionDate>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <type>Floor</type>
      </item>
      <item>
        <actionCode>H12410</actionCode>
        <text>Placed on the Union Calendar, Calendar No. 138.</text>
        <links />
        <committee />
        <actionDate>2017-07-11</actionDate>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <type>Calendars</type>
      </item>
      <item>
        <actionCode>H12200</actionCode>
        <text>Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-201.</text>
        <links>
          <link>
            <name>H. Rept. 115-201</name>
            <url>https://www.congress.gov/congressional-report/115th-congress/house-report/201</url>
          </link>
        </links>
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <actionDate>2017-07-11</actionDate>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <type>Committee</type>
      </item>
      <item>
        <actionCode>5000</actionCode>
        <text>Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-201.</text>
        <links>
          <link>
            <name>H. Rept. 115-201</name>
            <url>https://www.congress.gov/congressional-report/115th-congress/house-report/201</url>
          </link>
        </links>
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <actionDate>2017-07-11</actionDate>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2017-06-07</actionDate>
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Ordered to be Reported (Amended) by the Yeas and Nays: 54 - 0.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2017-06-07</actionDate>
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Committee Consideration and Mark-up Session Held.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2017-05-18</actionDate>
        <committee>
          <name>Health Subcommittee</name>
          <systemCode>hsif14</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2017-05-18</actionDate>
        <committee>
          <name>Health Subcommittee</name>
          <systemCode>hsif14</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Subcommittee Consideration and Mark-up Session Held.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2017-05-16</actionDate>
        <committee>
          <name>Health Subcommittee</name>
          <systemCode>hsif14</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionCode>H11100</actionCode>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <links />
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <actionDate>2017-05-16</actionDate>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionCode>Intro-H</actionCode>
        <text>Introduced in House</text>
        <links />
        <committee />
        <actionDate>2017-05-16</actionDate>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionCode>1000</actionCode>
        <text>Introduced in House</text>
        <links />
        <committee />
        <actionDate>2017-05-16</actionDate>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <type>IntroReferral</type>
      </item>
    </actions>
    <sponsors>
      <item>
        <district>2</district>
        <firstName>GREG</firstName>
        <fullName>Rep. Walden, Greg [R-OR-2]</fullName>
        <state>OR</state>
        <middleName />
        <bioguideId>W000791</bioguideId>
        <identifiers>
          <bioguideId>W000791</bioguideId>
          <lisID>1596</lisID>
          <gpoId>8115</gpoId>
        </identifiers>
        <party>R</party>
        <byRequestType />
        <lastName>WALDEN</lastName>
      </item>
    </sponsors>
    <billNumber>2430</billNumber>
    <createDate>2017-05-17T03:11:41Z</createDate>
    <summaries>
      <billSummaries>
        <item>
          <lastSummaryUpdateDate>2017-07-25T14:54:32Z</lastSummaryUpdateDate>
          <text><![CDATA[<p><b>FDA Reauthorization Act of 2017</b></p> <p><i>Prescription Drug User Fee Amendments of 2017</i></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to extend through FY2022 and revise Food and Drug Administration (FDA) user fees for new drug applications. User fees are eliminated for supplements to new drug applications and drug manufacturing facilities.</p> <p><i>Medical Device User Fee Amendments of 2017</i></p> <p>The bill extends through FY2022 and revises FDA user fees for medical devices. A user fee is established for requests to classify devices that are not substantially equivalent to marketed devices. The FDA is no longer granted the discretion to waive or reduce fees in the interest of public health.</p> <p>The FDA must establish a pilot program to accredit testing laboratories to determine whether medical devices conform to performance standards.</p> <p>The bill revises the types of medical devices that the FDA may accredit third parties to review. </p> <p><i>Generic Drug User Fee Amendments of 2017</i></p> <p>The bill extends through FY2022 and revises FDA user fees for generic drugs. User fees are eliminated for supplements to generic drug applications. An annual fee is assessed on holders of approved generic drug applications. </p> <p><i>Biosimilar User Fee Amendments of 2017</i></p> <p>The bill extends through FY2022 and revises FDA user fees for biosimilars. (Biosimilars are biological products approved by the FDA based on their similarity to an already-approved biological product.) User fees are eliminated for supplements to biosimilar applications and biosimilar manufacturing facilities. An annual fee is assessed on holders of approved applications for biosimilars. The bill sets the annual amount of revenue that must be generated by fees.</p> The bill extends through FY2022 programs and policies including Critical Path Public-Private Partnerships, support for development of medical products for rare conditions, and the program to conduct pediatric studies of drugs.]]></text>
          <name>Introduced in House</name>
          <actionDesc>Introduced in House</actionDesc>
          <updateDate>2017-05-16T04:00:00Z</updateDate>
          <actionDate>2017-05-16</actionDate>
          <versionCode>00</versionCode>
        </item>
      </billSummaries>
    </summaries>
    <committees>
      <billCommittees>
        <item>
          <type>Standing</type>
          <subcommittees>
            <item>
              <systemCode>hsif14</systemCode>
              <name>Health Subcommittee</name>
              <activities>
                <item>
                  <date>2017-05-18T19:03:32Z</date>
                  <name>Reported by</name>
                </item>
                <item>
                  <date>2017-05-18T19:02:48Z</date>
                  <name>Markup by</name>
                </item>
                <item>
                  <date>2017-05-16T18:54:43Z</date>
                  <name>Referred to</name>
                </item>
              </activities>
            </item>
          </subcommittees>
          <name>Energy and Commerce Committee</name>
          <chamber>House</chamber>
          <systemCode>hsif00</systemCode>
          <activities>
            <item>
              <date>2017-07-11T16:17:58Z</date>
              <name>Reported by</name>
            </item>
            <item>
              <date>2017-06-07T13:32:24Z</date>
              <name>Markup by</name>
            </item>
            <item>
              <date>2017-05-16T16:04:00Z</date>
              <name>Referred to</name>
            </item>
          </activities>
        </item>
      </billCommittees>
    </committees>
    <title>FDA Reauthorization Act of 2017</title>
    <introducedDate>2017-05-16</introducedDate>
    <version>1.0.0</version>
    <cboCostEstimates>
      <item>
        <title>H.R. 2430, FDA Reauthorization Act of 2017</title>
        <pubDate>2017-07-11T18:21:11Z</pubDate>
        <url>https://www.cbo.gov/publication/52888</url>
      </item>
    </cboCostEstimates>
    <congress>115</congress>
    <titles>
      <item>
        <title>Biosimilar User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>Short Titles as Passed House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType>Short Titles House of Representatives</parentTitleType>
      </item>
      <item>
        <title>Generic Drug User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>Short Titles as Passed House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType>Short Titles House of Representatives</parentTitleType>
      </item>
      <item>
        <title>Medical Device User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>Short Titles as Passed House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType>Short Titles House of Representatives</parentTitleType>
      </item>
      <item>
        <title>Prescription Drug User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>Short Titles as Passed House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType>Short Titles House of Representatives</parentTitleType>
      </item>
      <item>
        <title>Biosimilar User Fee Amendments of 2017</title>
        <chamberName />
        <titleType>Short Titles as Introduced for portions of this bill</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
      <item>
        <title>Generic Drug User Fee Amendments of 2017</title>
        <chamberName />
        <titleType>Short Titles as Introduced for portions of this bill</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
      <item>
        <title>Medical Device User Fee Amendments of 2017</title>
        <chamberName />
        <titleType>Short Titles as Introduced for portions of this bill</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
      <item>
        <title>Prescription Drug User Fee Amendments of 2017</title>
        <chamberName />
        <titleType>Short Titles as Introduced for portions of this bill</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
      <item>
        <title>FDA Reauthorization Act of 2017</title>
        <chamberName>House</chamberName>
        <titleType>Short Titles as Passed House</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType>Short Titles House of Representatives</parentTitleType>
      </item>
      <item>
        <title>FDA Reauthorization Act of 2017</title>
        <chamberName />
        <titleType>Short Titles as Introduced</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
      <item>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.</title>
        <chamberName />
        <titleType>Official Title as Introduced</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
      <item>
        <title>FDA Reauthorization Act of 2017</title>
        <chamberName />
        <titleType>Display Title</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
      <item>
        <title>Biosimilar User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>(Extracted from GPO) Short Titles as Passed House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType />
      </item>
      <item>
        <title>Generic Drug User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>(Extracted from GPO) Short Titles as Passed House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType />
      </item>
      <item>
        <title>Medical Device User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>(Extracted from GPO) Short Titles as Passed House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType />
      </item>
      <item>
        <title>Prescription Drug User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>(Extracted from GPO) Short Titles as Passed House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType />
      </item>
      <item>
        <title>FDA Reauthorization Act of 2017</title>
        <chamberName>House</chamberName>
        <titleType>(Extracted from GPO) Short Titles as Passed House</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType />
      </item>
      <item>
        <title>Biosimilar User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>(Extracted from GPO) Short Titles as Reported to House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType />
      </item>
      <item>
        <title>Generic Drug User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>(Extracted from GPO) Short Titles as Reported to House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType />
      </item>
      <item>
        <title>Medical Device User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>(Extracted from GPO) Short Titles as Reported to House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType />
      </item>
      <item>
        <title>Prescription Drug User Fee Amendments of 2017</title>
        <chamberName>House</chamberName>
        <titleType>(Extracted from GPO) Short Titles as Reported to House for portions of this bill</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType />
      </item>
      <item>
        <title>FDA Reauthorization Act of 2017</title>
        <chamberName>House</chamberName>
        <titleType>(Extracted from GPO) Short Titles as Reported to House</titleType>
        <chamberCode>H</chamberCode>
        <parentTitleType />
      </item>
      <item>
        <title>Biosimilar User Fee Amendments of 2017</title>
        <chamberName />
        <titleType>(Extracted from GPO) Short Titles as Introduced for portions of this bill</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
      <item>
        <title>Generic Drug User Fee Amendments of 2017</title>
        <chamberName />
        <titleType>(Extracted from GPO) Short Titles as Introduced for portions of this bill</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
      <item>
        <title>Medical Device User Fee Amendments of 2017</title>
        <chamberName />
        <titleType>(Extracted from GPO) Short Titles as Introduced for portions of this bill</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
      <item>
        <title>Prescription Drug User Fee Amendments of 2017</title>
        <chamberName />
        <titleType>(Extracted from GPO) Short Titles as Introduced for portions of this bill</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
      <item>
        <title>FDA Reauthorization Act of 2017</title>
        <chamberName />
        <titleType>(Extracted from GPO) Short Titles as Introduced</titleType>
        <chamberCode />
        <parentTitleType />
      </item>
    </titles>
    <updateDate>2017-07-28T10:31:48Z</updateDate>
    <calendarNumbers>
      <item>
        <calendar>U00138</calendar>
        <number />
      </item>
      <item>
        <calendar>Senate Calendar of Business</calendar>
        <number />
      </item>
      <item>
        <calendar>Senate Calendar of Business</calendar>
        <number>0174</number>
      </item>
    </calendarNumbers>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

